Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elders rural services australia limited - alpha-cypermethrin; hydrocarbon liquid - emulsifiable concentrate - alpha-cypermethrin pyrethroid active 100.0 g/l; hydrocarbon liquid solvent other 760.0 g/l - insecticide

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance pharmaceuticals ltd - alpha tocopheryl acetate - oral suspension - 100mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxycillin trihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

alpha crop protection pty ltd - 2,4-d present as the dimethylamine and diethanolamine sa - aqueous concentrate - 2,4-d present as the dimethylamine and diethanolamine sa phenoxy acids-2,4-d active 625.0 g/l - herbicide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

hemani industries limited - alpha-cypermethrin - unknown - alpha-cypermethrin pyrethroid active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fatro s.p.a. - dl-alpha-tocopherol acetate 50% - unknown - dl-alpha-tocopherol acetate 50% vitamin-e active 0.0 - active constituent

Australia - English - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 1000 mg - solution - excipient ingredients: monobasic sodium phosphate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1-antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 4000 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 500 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.